Role of Droperidol in Postoperative Vomiting
Launched by ARISTOTLE UNIVERSITY OF THESSALONIKI · Jun 19, 2008
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
In this prospective, randomized, placebo-controlled study, the researchers determined whether 0.625 mg (1/2 amp) IV droperidol given at the initiation of general anesthesia reduces the incidence of immediate and delayed post operative nausea and vomiting (PONV) in laparoscopic cholecystectomy population. One hundred patients receiving general anesthesia for laparoscopic cholecystectomy received droperidol 0.625 mg (1/2 amp) mg or placebo prior operation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient more than 18 years old
- • Patients scheduled for laparoscopic cholecystectomy
- • Informed consent obtained from the patient
- Exclusion Criteria:
- • Age \< 18 years old
- • Contraindication to laparoscopic surgery
- • Present a severe depressive syndrome
- • Pregnancy women
- • Trouble of cardiac rate
- • Alcoholism
- • Contra-indication for Droperidol prescription
About Aristotle University Of Thessaloniki
Aristotle University of Thessaloniki (AUTH) is a prestigious institution in Greece, renowned for its commitment to advancing knowledge and innovation in the field of clinical research. As a leading academic sponsor of clinical trials, AUTH leverages its extensive resources and expertise to conduct rigorous studies that contribute to the understanding of various medical conditions and the development of novel therapeutic interventions. The university fosters collaboration among multidisciplinary teams, ensuring adherence to the highest ethical standards and regulatory requirements while promoting scientific excellence and enhancing patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Thessaloniki, Macedonia, Greece
Patients applied
Trial Officials
Isaak Kesisoglou
Principal Investigator
Associate Professor in Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials